90 results about "Right heart ventricle" patented technology

The invention relates to a medical prosthesis, and in particular a heart valve substitute comprising a pliant tubular conduit mounted on a resilient annular frame and tethered to a non-perforating anchor within the right or left ventricle of the heart, wherein the pliant tubular conduit is a reciprocating mechanical member that is compressed by pressurized working fluid within the ventricle during systole.

Method and system for computation of advanced heart measurements from medical images and data; and therapy planning using a patient-specific multi-physics fluid-solid heart model is disclosed. A patient-specific anatomical model of the left and right ventricles is generated from medical image patient data. A patient-specific computational heart model is generated based on the patient-specific anatomical model of the left and right ventricles and patient-specific clinical data. The computational model includes biomechanics, electrophysiology and hemodynamics. To generate the patient-specific computational heart model, initial patient-specific parameters of an electrophysiology model, initial patient-specific parameters of a biomechanics model, and initial patient-specific computational fluid dynamics (CFD) boundary conditions are marginally estimated. A coupled fluid-structure interaction (FSI) simulation is performed using the initial patient-specific parameters, and the initial patient-specific parameters are refined based on the coupled FSI simulation. The estimated model parameters then constitute new advanced measurements that can be used for decision making.

The disclosure provides methods and apparatus of left ventricular pacing including automated adjustment of a atrio-ventricular (AV) pacing delay interval and intrinsic AV nodal conduction testing. It includes—upon expiration or reset of a programmable AV Evaluation Interval (AVEI)—performing the following: temporarily increasing a paced AV interval and a sensed AV interval and testing for adequate AV conduction and measuring an intrinsic atrio-ventricular (PR) interval for a right ventricular (RV) chamber. Thus, in the event that the AV conduction test reveals a physiologically acceptable intrinsic PR interval then storing the physiologically acceptable PR interval in a memory structure (e.g., a median P-R from one or more cardiac cycles). In the event that the AV conduction test reveals an AV conduction block condition or if unacceptably long PR intervals are revealed then a pacing mode-switch to a bi-ventricular (Bi-V) pacing mode occurs and the magnitude of the AVEI is increased.

This document discusses, among other things, systems, devices, and methods measure an impedance and, in response, adjust an atrioventricular (AV) delay or other cardiac resynchronization therapy (CRT) parameter that synchronizes left and right ventricular contractions. A first example uses parameterizes a first ventricular volume against a second ventricular volume during a cardiac cycle, using a loop area to create a synchronization fraction (SF). The CRT parameter is adjusted in closed-loop fashion to increase the SF. A second example measures a septal-freewall phase difference (PD), and adjusts a CRT parameter to decrease the PD. A third example measures a peak-to-peak volume or maximum rate of change in ventricular volume, and adjusts a CRT parameter to increase the peak-to-peak volume or maximum rate of change in the ventricular volume.

Systems and methods for selecting a cardiac resynchronization therapy (CRT) mode involve sensing electrocardiogram (ECG) data for a patient, identifying a PR interval from the sensed ECG data, comparing the PR interval to a threshold, and selecting a CRT mode by selecting between a synchrony optimization mode and a preload optimization mode, the selection based on the comparison of the PR interval to the threshold. A synchrony optimization mode may be selected if the parameter is less than the threshold, and may optimize CRT for fusion between a left ventricular pulse and an intrinsic wavefront. The preload optimization mode may be selected if the parameter is greater than the threshold, and may optimize CRT for fusion between respective wavefronts of the left ventricular pace and a right ventricular pace.

Emerging evidence indicates that diminished activity of the vasoprotective axis of the renin-angiotensin system, constituting angiotensin converting enzyme2 (ACE2) and its enzymatic product, angiotensin-(1-7) [Ang-(1-7)] contribute to pulmonary hypertension (PH). However, clinical success for long-term delivery of ACE2 or Ang-(1-7) would require stability and ease of administration to increase patient compliance. Chloroplast expression of therapeutic proteins enables their bioencapsulation within plant cells to protect from acids and gastric enzymes; fusion to a transmucosal carrier facilitates effective systemic absorption. Oral feeding of rats with bioencapsulated ACE2 or Ang-(1-7) attenuated monocrotaline (MCT)-induced increase in right ventricular systolic pressure, decreased pulmonary vessel wall thickness and improved right heart function in both prevention and reversal protocols. Furthermore, combination of ACE2 and Ang-(1-7) augmented the beneficial effects against cardio-pulmonary pathophysiology induced by MCT administration.Experiments have also been performed which indicate that this approach is also suitable for the treatment or inhibition of experimental uveitis and autoimmune uveoretinitis These studies provide proof-of-concept for a novel low-cost oral ACE2 or Ang-(1-7) delivery system using transplastomic technology for pulmonary and ocular disease therapeutics.

The invention is directed to methods and devices for optimization of biventricular pacing in subjects suffering from heart failure. The invention provides for a method for selection of optimal parameters for permanent pacing, the method comprising: positioning one or more arrays of lead wires in the posterior pericardium of a subject, wherein the arrays are connected to a multiplexing switch, wherein the switch is connected to a computer processor and a biventricular pacemaker; from the computer processor, generating a randomized sequence of: (i) pacing sites (VPS), (ii) right ventricular-left ventricular delays (RLDs), (iii) heart rates (HR); (iv) atrioventricular delays (AVDs), (v) or any combination or permutation thereof; and determining cardiac output in real time, using aortic flow velocity, thereby allowing selection of optimal parameters for permanent pacing.

An ultrasound imaging system is for determining stroke volume and / or cardiac output. The imaging system may include a transducer unit for acquiring ultrasound data of a heart of a subject (or an inputfor receiving the acquired ultrasound data), and a controller. The controller is adapted to implement a two-step procedure, the first step being an initial assessment step, and the second being an imaging step having two possible modes depending upon the outcome of the assessment. In the initial assessment procedure, it is determined whether regurgitant ventricular flow is present. This is performed using Doppler processing techniques applied to an initial ultrasound data set. If regurgitant flow does not exist, stroke volume is determined using segmentation of 3D ultrasound image data to identify and measure the volume of the left or right ventricle at each of end systole and end-diastole, the difference between them giving a measure of stroke volume. If regurgitant flow does exist, stroke volume is determined using Doppler techniques applied to ultrasound data continuously collected throughout a cardiac cycle.